Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus

被引:214
作者
Bonaccorso, S
Marino, V
Biondi, M
Grimaldi, F
Ippoliti, F
Maes, M [1 ]
机构
[1] CRC MH, Antwerp, Belgium
[2] Univ Roma La Sapienza, Hosp Psychiat, Rome, Italy
[3] Univ Roma La Sapienza, Dept Infect & Trop Dis, Rome, Italy
[4] Univ Roma La Sapienza, Dept Immunol, Rome, Italy
[5] Univ Hosp Maastricht, Dept Psychiat & Neuropsychol, NL-6202 AZ Maastricht, Netherlands
[6] Vanderbilt Univ, Dept Psychiat, Nashville, TN USA
关键词
inteferon-alpha; depression; cytokines; immunology; cytokine treatment;
D O I
10.1016/S0165-0327(02)00264-1
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Several studies found a high incidence rate of neuro-psychiatric complications during long-term therapy with interferon alpha (IFNalpha), e.g. slowness, severe fatigue, hypersomnia, lethargy, depressed mood, mnemonic troubles, irritability, short temper, emotional lability, social withdrawal, and lack of concentration. The aim of this study was to examine the incidence of depressed mood and major depression in patients who were treated with IFNalpha. Methods: 30 patients, affected by chronic active C-hepatitis, have been evaluated at baseline and 3 months after IFNalpha treatment. The evaluation consisted of psychometric assessments employing the DSM-IV criteria and the Montgomery Asberg Depression Rating Scale (MADRS). Results: At end-point, 40.7% of the patients suffered from a full blown major depression, according to the DSM-IV criteria for major depression. IFNa treatment induced a significant increase in the MADRS score from baseline to 3 months later. The MADRS items which were significantly increased at end-point were: expressed and unexpressed sadness; irritability; insomnia; loss of appetite; and asthenia. Discussion: The results show that prolonged IFNalpha treatment may induce depressive symptoms and major depression in a considerable number of subjects. (C) 2002 Published by Elsevier Science B.V.
引用
收藏
页码:237 / 241
页数:5
相关论文
共 25 条
[1]   NEUROPSYCHIATRIC MANIFESTATIONS OF HUMAN-LEUKOCYTE INTERFERON THERAPY IN PATIENTS WITH CANCER [J].
ADAMS, F ;
QUESADA, JR ;
GUTTERMAN, JU .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1984, 252 (07) :938-941
[2]  
CAVAILLON JM, 1996, INTERLEUKIN, V6
[3]   Depression, stress and immunological activation: The role of cytokines in depressive disorders [J].
Connor, TJ ;
Leonard, BE .
LIFE SCIENCES, 1998, 62 (07) :583-606
[4]  
Dafny N, 1996, BRAIN RES, V734, P269, DOI 10.1016/S0006-8993(96)00650-6
[5]   IMMUNE-RESPONSE PRODUCTS ALTER CNS ACTIVITY - INTERFERON MODULATES CENTRAL OPIOID FUNCTIONS [J].
DAFNY, N ;
LEE, JR ;
DOUGHERTY, PM .
JOURNAL OF NEUROSCIENCE RESEARCH, 1988, 19 (01) :130-139
[6]  
DUSHEIKO G, 1997, HEPATOLOGY, V3, P121
[7]   A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alfa interferon [J].
Fattovich, G ;
Giustina, G ;
Favarato, S ;
Ruol, A ;
Macarri, G ;
Orlandi, F ;
Iaquinto, G ;
Ambrosone, L ;
Francavilla, A ;
Pastore, G ;
Santantonio, MT ;
Romagno, D ;
Bolondi, L ;
Sofia, S ;
Marchesini, A ;
Pisi, E ;
Mazzella, G ;
Roda, E ;
Attaro, L ;
Chiodo, F ;
Mori, F ;
Verucchi, G ;
Lanzini, A ;
Salmi, A ;
Calvi, B ;
Bozzetti, F ;
Radaeli, E ;
Bernasconi, M ;
Pilleri, G ;
Bacca, D ;
Romano, G ;
Mastrapasqua, G ;
Cozzolongo, R ;
Cacopardo, B ;
Nunnari, A ;
Blasi, A ;
Sala, LO ;
Minoli, G ;
Sangiovanni, A ;
Spinzi, GC ;
Colombo, A ;
Camassa, M ;
Riva, D ;
Maggi, G ;
Boccia, S ;
Gualandi, G ;
Nucci, A ;
Pacini, F ;
Marino, N ;
Mazzotta, F .
JOURNAL OF HEPATOLOGY, 1996, 24 (01) :38-47
[8]  
Hardy P, 1996, GASTROEN CLIN BIOL, V20, P255
[9]   SUICIDE ASSOCIATED WITH ALFA-INTERFERON THERAPY FOR CHRONIC VIRAL-HEPATITIS [J].
JANSSEN, HLA ;
BROUWER, JT ;
VANDERMAST, RC ;
SCHALM, SW .
JOURNAL OF HEPATOLOGY, 1994, 21 (02) :241-243
[10]  
LIEBERMAN A, 1989, P NATL ACAD SCI USA, V96, P6348